{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-093997","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.620569+00:00","generated_at":"2026-05-15T19:54:29.203728+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BBOT reports Q4 net loss $38.8M; cash runway into 2028; pipeline advances","bullets":["Q4 2025 net loss $38.8M (vs $19.7M in Q4 2024); full year net loss $134M (vs $74.3M).","Cash and equivalents $425.5M; expected to fund operations into 2028.","R&D expenses Q4 $38.1M (vs $19.5M); G&A $5.3M (vs $2.3M); increases driven by clinical and manufacturing.","BBO-8520 monotherapy 65% ORR in KRAS G12C NSCLC; BBO-11818 first confirmed PR in PDAC; BBO-10203 no hyperglycemia.","Clinical data readouts across all three programs expected in H2 2026; internal combinations opening later in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-093997","json":"https://secwatch.observer/filing/0001193125-26-093997.json","markdown":"https://secwatch.observer/filing/0001193125-26-093997.md","text":"https://secwatch.observer/filing/0001193125-26-093997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/0001193125-26-093997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/bbot-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:54:29.203728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4e660ec9bdc942b13eb3a4bb4a8a4ab94bc0e24","claim":"BridgeBio Oncology Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/0001193125-26-093997-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}